Benzodiazepine receptor Inhibitors
1 drugsAbout Benzodiazepine receptor
The Benzodiazepine receptor is a key component of the central nervous system (CNS). It modulates the effects of the neurotransmitter GABA, influencing sedative, anxiolytic, and muscle relaxant responses.
Currently, there is no genetic evidence available linking the Benzodiazepine receptor to specific diseases. However, its therapeutic importance is highlighted by existing drugs targeting it for CNS-related conditions.
The Benzodiazepine receptor is targeted by one FDA-approved drug, FELBAMATE, a small molecule. ANI PHARMS holds the approval for FELBAMATE, which has three indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Cesarean Section Complications with only 1 trials.
Top Benzodiazepine receptor Drugs
ANI PHARMS is the sole company with an approved drug targeting the Benzodiazepine receptor.
Low competition suggests a potential market entry opportunity, but also indicates possible challenges in the target space.
Benzodiazepine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Benzodiazepine receptor, using small molecule modality.
The exclusive use of small molecules indicates a whitespace opportunity for alternative modalities like antibodies or peptides.
Benzodiazepine receptor Drug Approval Timeline (2011 - 2011)
The first and most recent drug approval for this target was FELBAMATE in 2011.
A single approval over a decade ago suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 5 clinical trials targeting Benzodiazepine receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities